U.S. Banks Stock News

BML Capital Management has exited its entire position in Alumis (NasdaqGS:ALMS). The move aligns with Alumis filing a new shelf registration. The company is also preparing to appear at several major investor conferences. BML Capital Management stepping away from Alumis puts fresh attention on how the market views the biotech name. Alumis, which focuses on drug development, now heads into a period where it is updating its capital markets toolkit through a shelf registration while also...

If you are wondering whether NXP Semiconductors' current share price lines up with its underlying worth, you are not alone. This article is built to help you judge that for yourself using clear valuation checks. The stock last closed at US$222.13, with a 4.9% decline over the past 7 days and a 9.7% decline over the past 30 days, while its year to date return is 0.4% and its 1 year return is 4.4%, compared with 23.8% over 3 years and 24.9% over 5 years. Recent attention on NXP Semiconductors...

Uber Technologies (UBER) closed out FY 2025 with Q4 revenue of US$14.4b and basic EPS of US$0.14, alongside net income of US$296m, capping a year where trailing twelve month revenue reached US$52.0b and EPS came in at US$4.82. Over recent quarters, the company has seen revenue move from US$11.5b in Q1 2025 to US$13.5b in Q3 and then US$14.4b in Q4. Quarterly EPS shifted from US$0.85 in Q1 to US$3.18 in Q3 before landing at US$0.14 in the latest period, setting up a results season that puts...

If you are wondering whether Roper Technologies is starting to look interesting at its current share price, this article will walk through what that might mean for you as an investor. The stock last closed at US$351.00, with returns of a 3.8% decline over 7 days, 19.6% decline over 30 days, 19.2% decline year to date, 39.4% decline over 1 year, 16.6% decline over 3 years, and 9.6% decline over 5 years. Recent news around Roper has focused on its positioning as a diversified software and...

GRAIL, Inc. previously submitted the final module of its Premarket Approval application to the U.S. FDA for its Galleri multi-cancer early detection test, drawing on performance and safety data from the large PATHFINDER 2 and NHS-Galleri trials and supported by a bridging analysis to the updated test version. This milestone builds on the FDA’s earlier Breakthrough Device designation and centers on extensive real-world screening data to assess Galleri’s clinical utility. We’ll explore how...

If you are trying to work out whether Materion’s share price still offers value at its current level, the key question is how that price lines up against what the business may be worth. The stock last closed at US$145.83, with returns of 2.8% over 7 days, 8.3% over 30 days, 13.5% year to date, 43.6% over 1 year, 73.7% over 3 years and 115.6% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on...

If you are wondering whether Aptiv's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. Aptiv's stock last closed at US$79.72, with returns of 1.1% over 7 days, a 3.5% decline over 30 days, 1.6% year to date, a 25.6% gain over 1 year, and declines of 31.3% and 48.2% over 3 and 5 years respectively. Taken together, these figures give a mixed signal about growth potential and risk perception. Recent...

Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment. The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables. Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock. Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...

If you are trying to figure out whether Molina Healthcare's share price reflects its true worth, the starting point is understanding how its current market price compares with a range of valuation checks. The stock last closed at US$176.84, with returns of a 4.4% decline over 7 days, 4.3% decline over 30 days, 0.9% decline year to date, 38.0% decline over 1 year, 41.3% decline over 3 years, and 18.2% decline over 5 years, which may have shifted how investors see its potential and its...

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...

To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...

BioNTech (NasdaqGS:BNTX) has created a new Chief People Officer role. Kylie Jimenez has been appointed to the position, effective immediately. The move is tied to BioNTech’s goal of becoming a multi product oncology leader beyond its COVID 19 work. BioNTech, known widely for its COVID 19 vaccine partnership, is working to build a broader pipeline in oncology and other therapeutic areas. The new Chief People Officer role indicates that leadership views talent, organizational design, and...

If you have ever wondered whether Shake Shack's current share price reflects what you are actually getting as an investor, you are not alone. The stock recently closed at US$93.07, with returns of 5.7% over 7 days, 3.6% over 30 days, 11.5% year to date, 64.1% over 3 years, and a 19.2% decline over 1 year. Taken together, this gives a mixed picture of how the market has been reassessing it over different timeframes. Recent coverage has focused on Shake Shack as a branded fast casual player...

The New York Times (NYT) closed out FY 2025 with Q4 revenue of US$802.3 million and basic EPS of US$0.80, compared with US$719.5 million of revenue and EPS of US$0.75 in the prior year’s Q4, pointing attention squarely to how efficiently the business is turning its top line into profit. Over the past six quarters, the company has seen quarterly revenue move from US$633.6 million in Q3 2024 to US$694.1 million in Q3 2025 and then to US$802.3 million in Q4 2025, while basic EPS ranged from...

UiPath, Inc. ( NYSE:PATH ) shares have had a horrible month, losing 30% after a relatively good period beforehand. The...

As you might know, Broadridge Financial Solutions, Inc. ( NYSE:BR ) just kicked off its latest quarterly results with...

Sempra subsidiaries Southern California Gas Co. and San Diego Gas & Electric have petitioned California regulators to drop a 5% hydrogen blending demonstration requirement. The filing argues that existing research and operational data are sufficient to assess low level hydrogen blending safety without new pilot projects. The request targets rules that would have required utilities to complete demonstration projects before regulators consider a systemwide hydrogen blending standard. Sempra,...

Whirlpool (NYSE:WHR) has been named to TIME's inaugural "America’s Most Iconic Companies" list. The company is the only home appliance brand included, recognized for its cultural impact and commitment to U.S. manufacturing. This recognition highlights Whirlpool’s long history in American households and its continued domestic production footprint. For investors tracking Whirlpool at a share price of $85.09, this recognition arrives alongside mixed recent return data. The stock is up 10.6%...

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This step moves the investigational combination closer to potential commercial use in the United States. For investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a...

If you are wondering whether Janus Henderson Group's current share price still makes sense, you are not alone. Many investors are asking if the stock offers solid value at today's level. The shares last closed at US$48.19, with returns of 0.5% over 7 days, 0.3% over 30 days, 0.9% year to date and 9.3% over 1 year, while 3-year and 5-year returns sit at very large levels close to a 2x gain. Recent attention on Janus Henderson Group has been shaped by coverage of its position in the global...

Allstate (ALL) just wrapped up FY 2025 with Q4 revenue of US$17.3b and basic EPS of US$14.55, capping off a trailing twelve month stretch where revenue reached US$67.7b and EPS came in at US$38.56 alongside year over year earnings growth of 123.4%. Over the past few quarters, the company has seen revenue move from US$16.5b and EPS of US$7.16 in Q4 2024 to US$16.6b and EPS of US$7.86 in Q2 2025, then to US$17.3b and EPS of US$14.55 in Q4 2025, setting up a story where stronger profitability...

If you are wondering whether American Tower's current share price reflects its underlying worth, you are not alone; many investors are asking the same question right now. The stock last closed at US$171.49, with returns of 5.4% decline over 7 days, 2.5% decline over 30 days, 1.9% decline year to date and 6.5% decline over the past year, alongside 11.8% decline over 3 years and 12.8% decline over 5 years. Recent news coverage around American Tower has focused on its role in providing wireless...

TPG (NasdaqGS:TPG) has launched Third Wave Insurance, a new retail insurance brokerage platform. The business is led by industry veteran Brian Bair and formed in partnership with Palmer & Cay. The move extends TPG beyond its traditional alternative asset management roots into insurance distribution. For investors watching TPG at a current share price of $53.54, this new insurance brokerage venture adds another business line alongside its existing funds platform. The stock has seen a 23.1%...

LyondellBasell Industries (NYSE:LYB) is cutting global ethylene capacity and idling selected production through 2028 to address persistent weakness in chemicals markets. The company plans to divest four European assets as part of a broad portfolio overhaul aimed at focusing on higher value operations. These moves mark a clear inflection point for both LyondellBasell and the wider chemicals sector after a challenging period. LyondellBasell, trading at about $53.88, is taking these capacity...